冠状动脉介入术后双联抗血小板最佳疗程研究进展  

Optimal Duration of Dual Antiplatelet Therapy after Pereutaneous Coronary Intervention

作　　者：许晶晶[1] 袁晋青[1] 

机构地区：[1]北京协和医学院 中国医学科学院 阜外医院 心内科,北京市100037

出　　处：《中国分子心脏病学杂志》2014年第6期1162-1164,共3页Molecular Cardiology of China

基　　金：国家"十二五"科技支撑计划(2011BAI11B07)

摘　　要：冠状动脉介入治疗后服用双联抗血小板药物可减少心血管并发症的发生率,改善患者预后,但双联抗血小板治疗的具体时程存在争议。传统观点认为冠状动脉药物支架置入术后双联抗血小板药物应至少应用12个月,以减少支架内血栓的发生,但最新研究发现长期应用双联抗血小板药物并不增加患者获益。尤其是第二代药物洗脱支架问世后,双联抗血小板治疗时程已缩短至3个月。但也有研究者指出,短程双联抗血小板治疗可增加心脏不良事件的发生率。现根据最新临床研究,对冠状动脉介入术后双联抗血小板治疗时程问题进行讨论。Dual antiplatelet therapy after Coronary artery intervention can reduce the incidence of cardiovascular complications, and improve the prognosis.But the optimal duration of dual antiplatelet therapy is controversial.In order to reduce the occurrence of stent thrombosis,the traditional view is that the duration of dual antiplatelet therapy after Drug-eluting stent should be at least 12 months.New studies show that longterm application of dual antiplatelet drugs does not increase benefit. Especially after the appearance of the second generation drug-eluting stent, the duration of dual antiplatelet therapy has been reduced to 3 months.However,there are some researchers pointed that short-term dual antiplatelet therapy can increase the incidence of cardiovascular events. The latest clinical researches have been reviewed, and the optimal duration of dual antiplatelet therapy is discussed.

关 键 词：冠心病 介入治疗 抗血小板 疗程 

分 类 号：R541.4[医药卫生—心血管疾病]